H.I.G. Carves BioVectra from Mallinckrodt

H.I.G. Carves BioVectra from Mallinckrodt

Biopharmaceutical giant Mallinckrodt has agreed to sell its subsidiary BioVectra to H.I.G. Capital for $250 million. The purchase price is comprised of cash at closing of $135 million, a long-term note for $40 million, and contingent payments of up to $75 million. BioVectra is a contract development and manufacturing company that supplies ingredients for pharmaceutical […]

H.I.G. Exits AMPAC Fine Chemicals

H.I.G. Exits AMPAC Fine Chemicals

H.I.G. Capital has agreed to sell AMPAC Fine Chemicals to South Korean conglomerate SK Holdings. AMPAC Fine Chemicals (AFC) is a supplier of high value-added active pharmaceutical ingredients and intermediates used in treating diseases such as cancer, central nervous system (CNS) disorders and certain viral infections. Customers of AFC include blue-chip pharmaceutical and biotech companies. […]

SK Capital to Acquire Perrigo API

SK Capital to Acquire Perrigo API

SK Capital has signed an agreement to acquire Perrigo API, the active pharmaceutical ingredients business of publicly-traded Perrigo Company. The transaction is expected to close during the fourth quarter and the company will be renamed prior to closing. Perrigo API is a developer and manufacturer of generic active pharmaceutical ingredients (APIs) and finished dose forms […]